Golgi Apparatus & PMM2-CDG: Comprehensive Study Notes

Golgi Apparatus: Structure, Location, and Functions

• Also known as the Golgi body or Golgi apparatus; a membrane-bound organelle of eukaryotic cells consisting of a series of flattened, stacked pouches called cisternae
• Location: in the cytoplasm, near the endoplasmic reticulum (ER) and close to the cell nucleus
• Plant cells can contain hundreds of Golgi bodies; many cell types contain one or several

Structure

• Comprised of cisternae organized in a stack; membrane-bound compartments that process and sort cargo
• Functionally organized to receive cargo from the ER, modify it, and dispatch it onward

Functions of the Golgi Body

• Transporting, modifying, and packaging proteins and lipids into vesicles for delivery to targeted destinations
• Modifications performed (glycosylation) affect stability, folding, trafficking, and recognition of proteins
• Key process: Glycosylation
  • N-glycosylation: attachment of sugars to asparagine residues; occurs in both the ER and the Golgi apparatus
  • O-glycosylation: attachment of sugars to serine/threonine residues; occurs in the Golgi apparatus only
• Packaging of cargo into vesicles for delivery
  • Secretory vesicles → released outside the cell
  • Transport vesicles → sent to other organelles (e.g., lysosomes)
  • Plasma membrane vesicles → inserted into the cell membrane
• Essential role in coordinating trafficking from the ER to various intracellular and extracellular destinations

PMM2- CDG: Overview and Context

• PMM2-CDG stands for Phosphomannomutase 2 Congenital Disorder of Glycosylation
• PMM2-CDG is part of a broader group of disorders known as congenital disorders of glycosylation (CDG)
• CDGs were first reported in the medical literature in 1980 by Dr. Jaak Jaeken et al.; PMM2-CDG is the most common form
• PMM2 is an enzyme that plays a crucial role in N-glycosylation, the process that builds and attaches N-linked oligosaccharides to proteins
• In PMM2-CDG, mutations in the PMM2 gene reduce or abolish PMM2 enzyme activity, leading to defective glycosylation and multisystem disease

PMM2-CDG: Genetics and Inheritance

• Inheritance: autosomal recessive
  • An affected child typically inherits two defective PMM2 gene copies (one from each parent)
• Population-level probabilities (assuming carrier parents):
  • P(\text{affected}) = \frac{1}{4} = 25\%
  • P(\text{carrier}) = \frac{1}{2} = 50\%
  • P(\text{unaffected}) = \frac{1}{4} = 25\%
• The condition is multisystemic and highly variable in type and severity, even within families

PMM2-CDG: Cause and Pathophysiology

• Cause: mutations in the PMM2 gene, which encodes the phosphomannomutase 2 enzyme
• Role of PMM2: critical in N-glycosylation; builds and attaches N-linked oligosaccharides to proteins
• Consequence of PMM2 mutations: reduced/abnormal PMM2 enzyme activity leading to defective glycosylation, resulting in inappropriate sugar chains attached to proteins
• Multisystem involvement arises because glycosylation is essential for the function of many tissues and organ systems

PMM2-CDG: Clinical Presentation (Symptoms)

• Onset and progression: signs and symptoms typically develop in infancy
• Neuromuscular and skeletal features
  • Peripheral neuropathy: reduced sensation and weakness in arms and legs
  • Impaired muscle coordination (ataxia)
  • Hypotonia (low muscle tone)
  • Kyphoscoliosis (spinal curvature)
  • Joint deformities (contractures)
• Ocular and facial features
  • Retinitis pigmentosa (vision loss)
  • Strabismus (eyes do not align)
  • Distinctive facial features: high forehead, triangular face, large ears, thin upper lip
• Endocrine and reproductive findings (sex-specific)
  • Females: hypergonadotropic hypogonadism (not going through puberty)
  • Males: normal puberty but small testes
• Growth and development
  • Developmental delay
  • Failure to gain weight and grow at expected rate (failure to thrive)
  • Underdeveloped cerebellum (coordination issues)
• Other systemic involvement
  • Liver and cardiac involvement
  • Coagulation issues
  • Abnormal fat distribution; retracted/inverted nipples
  • Eyes that do not look in the same direction (strabismus) and other multi-system signs

PMM2-CDG: Diagnosis

• Based on the presence of multisystemic symptoms compatible with a glycosylation disorder
• Genetic testing confirming PMM2 mutations is used to establish the diagnosis

PMM2-CDG: Treatment and Management Principles

• Current status: treatment options are limited and primarily symptomatic/as supportive management; no cure is available yet
• Goals of treatment: manage symptoms, support development, and monitor organ function
• Substrate (precursor) supplementation (upstream building blocks)
  • Rationale: bypass a blocked biochemical pathway or compensate for deficient enzyme activity
  • Analogy: it’s like a detour around a traffic jam
  • Effectiveness: uncertain and variable in PMM2-CDG
• Pharmacological chaperones
  • Small molecules that stabilize misfolded or unstable PMM2 enzymes to improve folding and function
  • Aims to increase PMM2 enzyme activity, even if only modestly
• Symptomatic and supportive treatments
  • Maintain caloric intake and proper nutrition, especially in infancy
  • Monitor hepatic function and potential effusions (pericardial, pleural)
  • Monitor for cardiac and liver involvement
  • Non-medical interventions: occupational, physical, and speech therapy; remedial education
  • Ophthalmic or surgical interventions for skeletal/neuromuscular issues
  • Endocrine management (e.g., hypothyroidism treatment, ovarian insufficiency management in appropriate patients)
  • Anticonvulsants for seizure control when needed
• Practical notes
  • Effectiveness of interventions is often uncertain and must be tailored to the individual
• The overall approach emphasizes supportive care and targeted therapies to improve quality of life and manage complications

PMM2-CDG: Case Study — SM MECA Analysis

• Patient: infant girl, seven months old
• Presenting features
  • Repeated pericardial effusion requiring pericardiocentesis and a pericardial window
  • Developmental delay and failure to thrive
  • Hypotonia, hyporeflexia
  • Dysmorphic features: high-arched palate, narrow palpebral fissures, inverted nipples, prominent supragluteal fat pads
  • Multisystem involvement
• Diagnostic trajectory
  • Initial clinical suspicion was cerebral palsy
  • The multisystem presentation, particularly cardiac involvement, shifted suspicion toward PMM2-CDG

Connections to Broader Concepts

• Golgi apparatus is central to protein maturation and trafficking in the secretory pathway (ER → Golgi → destination)
• Glycosylation (N- and O-linked) is a fundamental post-translational modification that influences protein stability, folding, trafficking, and cellular recognition
• PMM2-CDG exemplifies how defects in a single glycosylation step can produce widespread multisystem disease
• Therapeutic strategies for congenital disorders of glycosylation highlight broader themes in rare disease management: symptomatic care, gene/pathway-targeted approaches (e.g., chaperones, substrate supplementation), and the importance of early diagnosis

Key Takeaways and Concepts to Remember

• The Golgi apparatus modifies, sorts, and packages proteins and lipids via glycosylation and vesicle trafficking
• N-glycosylation involves sugar addition in both the ER and Golgi; O-glycosylation occurs in the Golgi only
• PMM2-CDG is the most common CDG form, caused by PMM2 mutations leading to defective N-glycosylation and multisystem disease
• In autosomal recessive PMM2-CDG, offspring risk follows Mendelian inheritance: 25% affected, 50% carrier, 25% unaffected
• Clinical features span neuromuscular, skeletal, ocular, endocrine, hepatic, cardiac, and growth domains
• Treatments are largely supportive, with experimental approaches including substrate supplementation and pharmacological chaperones; effectiveness varies by patient
• Case studies (e.g., SM MECA Analysis) illustrate how multisystem symptoms can redirect diagnosis toward PMM2-CDG, underscoring the need for comprehensive evaluation in atypical presentations

References Mentioned in Transcript

• Golgi Apparatus: What Is It, Location, Functions, and More. Osmosis (2025).
• Golgi apparatus | Britannica (2025).
• PMM2-congenital disorder of glycosylation. MedlinePlus.
• PMM2-CDG – Symptoms, Causes, Treatment | NORD. National Organization for Rare Disorders (2015).
• Treatment Options in Congenital Disorders of Glycosylation. PubMed Central.
• Marquardt, T., Oliveri, S., Ferrari, F., Manfrinati, A., & Pravettoni, G. (Frontiers in Genetics). Treatment Options in Congenital Disorders of Glycosylation.
• Osmosis reference on Golgi apparatus (online).